AT-28LONG-TERM SURVIVAL (OVER 15 YEARS) OF PATHOLOGICALLY CONFIRMED RECURRENT GLIOBLASTOMA MULTIFORME: A CASE REPORT

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (Suppl 5), p.v14-v15
• Main Authors: Janicki, Tomasz, Burzynski, Gregory, Burzynski, Stanislaw
• Format: Article
• Language: English
• Subjects: Abstracts
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nou237.28

Recurrent GBM carries poor prognosis with no standard therapy available. A 46-year-old Caucasian female underwent a partial resection of the tumor revealing a pathologic diagnosis of GBM. The patient then received radiation therapy (RT) at the dose of 5940 cGy over a six-week duration. After four months, she underwent a Gamma Knife procedure. Seven months later, she developed recurrence and underwent a second partial tumor resection. The pathology diagnosis again confirmed GBM. Magnetic resonance imaging (MRI) performed within one month revealed a recurrent tumor. A month later, treatment with IV infusions of antineoplastons A10 and AS2-1 (ANP) was initiated based on Special Exception into Protocol BT-20. During the baseline evaluation, the patient complained of marked weakness, short memory loss, frequent aura, loss of coordination, nausea, dizziness, difficulty walking, and speech problems. The dosage of A10 was gradually increased to 10.44 g/kg/d and AS2-1 to 0.17 g/kg/d. IV ANP was discontinued after 18.5 months due to complete response (CR). The only adverse event possibly related to the treatment was grade 1 skin rash, which resolved spontaneously. After stopping treatment with IV ANP, the patient started taking ANP A10 and AS2-1 orally (0.14 g/kg/d each). All treatments were discontinued after 31 months. The patient made a substantial recovery; she was able to walk without assistance and made progress in speech therapy. The baseline MRI revealed a right temporal enhancing lesion of 1.5 cm x 1.3 cm. Beginning fourteen months after the treatment start (10/14/1999), the MRI images showed a CR. Currently the patient is free from tumor recurrence, but had experienced some deterioration of her mental capacity due to chronic post-radiation toxicity. Her overall survival and progression-free survival is over 15 years.